Skip to main content
Publications
Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg C, Brown J, Dave V, Downey C, Shillington A, Katzenstein H, Kirker M, Hanson S, Liu F, Morris V, Bhanegaonkar A, Sonpavde G. Avelumab first-line maintenance (1LM) therapy for locally advanced/metastatic urothelial carcinoma (la/mUC): results from the realworld US PATRIOT-II study. Poster presented at the Academy of Managed Care Pharmacy (AMCP) 2024; April 15, 2024. New Orleans, LA. [abstract] J Manag Care Spec Pharm. 2024 Apr; 30(4-a):S123.
Phillips T, Lugtenburg P, Kalsekar A, Mutebi A, Wang A, Blaedel J, Kosa K, Martin S, Sacchi M, Kilavuz N, Thieblemont C. Improvements in patient-reported outcomes in relapsed or refractory large b-cell lymphoma patients treated with epcoritamab. Clin Lymphoma Myeloma Leuk. 2023 Nov 27;24(3):e78-e87.e. doi: 10.1016/j.clml.2023.11.005
Pluard T, Sandin R, Parikh R, Ward M, Stansfield L, Nham T, Esterberg L, Cha-Silva A, Shah B. Health care resource utilization and cost comparison among palbociclib, abemaciclib, and ribociclib in US patients with HR+/HER2− metastatic breast cancer. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2023 Oct; 29(10-a Suppl):S17-8. doi: 10.18553/jmcp.2023.29.10-a.s1
Cohen AD, Hari P, Htut M, Berdeja JG, Usmani SZ, Madduri D, Olyslager Y, Goldberg JD, Schecter JM, Jackson CC, Gries KS, Fastenau JM, Valluri S, Deraedt W, Akram M, Crawford R, Morrison R, Doward L, Morgan K, Seldam ST, Jakubowiak A, Jagannath S. Patient perceptions regarding ciltacabtagene autoleucel treatment: qualitative evidence from interviews with patients with relapsed/refractory multiple Myeloma in the CARTITUDE-1 study. Clin Lymphoma Myeloma Leuk. 2022 Nov 7;16:54. doi: /10.1016/j.clml.2022.10.001
Spira A, Zhou X, Chen L, Gnanasakthy A, Wang L, Ungar D, Curiel R, Liao L, Radford J, Kahl B. Health-related quality of life, symptoms, and tolerability of Loncastuximab Tesirine in patients with relapsed or refractory diffuse large b-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):158-68. doi: 10.1016/j.clml.2021.09.001
Carrico J, Jia X, Zhao Y, Zhang J, Brodtkorb T, Mendelsohn A, Wu J, Feldman S, Armstrong A. Cost-effectiveness and budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a Suppl):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Wheeler A, Ling W, Nadipelli V, Ronquest N, Aldridge A, Solem C, Peiper N, Learned S, Heidbreder C. Recovery from opioid use disorder post-monthly buprenorphine extended release treatment: 12-month longitudinal outcomes. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a):S14. doi: 10.18553/jmcp.2019.25.10-a.s1
Patterson BJ, Herring W, van Oorschot D, Curran D, Carrico J, Zhang Y, Ackerson BK, Bruxvoort K, Sy L, Tseng H. Public health and economic impact of adjuvanted recombinant zoster vaccine adoption for a large, integrated delivery network: utilizing real‐world epidemiological data in a budget impact model. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, DC. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a):S23.
Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for revaccinating U.S. adults previously vaccinated against herpes zoster. Poster presented at the 2017 AMCP NEXUS; October 18, 2017. Dallas, TX. [abstract] J Manag Care Spec Pharm. 2017 Oct; 23(10-a):S20.
Police RL, Trask PC, Wang J, Olivares R, Khan SB, Abbe A, Colosia AD, Njue AI, Sherrill EH, Ruiz-Soto R, Kaye JA, Hamadani M. Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):199-207. doi: 10.1016/j.clml.2014.09.008
Njue A, Colosia A, Trask PC, Olivares R, Khan S, Police R, Abbe A, Wang J, Kaye JA, Ruiz-Soto R, Awan F. Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):1-12. doi: 10.1016/j.clml.2014.03.006